Skip to main content
EDSA
NASDAQ Life Sciences

CEO Pardeep Nijhawan Continues Share Purchases, Adding $36,300 to Holdings

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.34
Mkt Cap
$35.647M
52W Low
$0.72
52W High
$5.399
52W Position info
503% above low
Off High info
20% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

EDSA has more than doubled off its 52-week low of $0.72.

Summary

Edesa Biotech's CEO, Pardeep Nijhawan, made an additional open-market purchase of $36,300 in common shares, reinforcing his conviction following recent positive clinical data.


Key Events · Ownership and Investor Activity · EDSA

  • CEO Increases Stake

    CEO Pardeep Nijhawan purchased 10,000 common shares for $36,300 at a price of $3.63 per share.

  • Reinforces Recent Insider Buying

    This purchase follows a larger $99,176 buy by the CEO just two days prior, indicating sustained confidence.

  • Amidst Positive Clinical Data

    The insider buying trend occurs shortly after the company announced positive Phase 3 data for its lead drug candidate, paridiprubart.

  • Signals Conviction Despite Financial Concerns

    The CEO's continued investment provides a positive signal of belief in the company's future, especially given the previously reported "going concern" uncertainty.


Analysis · EDSA · Life Sciences

This latest open-market purchase by CEO Pardeep Nijhawan, occurring just one day after a previous significant buy, signals continued strong insider confidence in Edesa Biotech. The transaction follows the recent announcement of positive Phase 3 data for paridiprubart and comes amidst the company's previously disclosed "going concern" uncertainty. The CEO's repeated investment, despite the company's financial challenges, suggests a belief in the long-term potential of the company's pipeline. Investors should view this as a positive signal of conviction from leadership.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EDSA was trading at $4.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $0.72 to $5.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EDSA - Latest Insights

EDSA
Nov 17, 2026, 9:25 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $1.91 info
Change: -$0.030 (-2%) info
Market Cap: $25.807M info
EDSA
Nov 09, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.35
Real-time Price: $1.91 info
Change: -$0.440 (-19%) info
Market Cap: $25.807M info
EDSA
Nov 09, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $1.91 info
Change: -$0.6182 (-24%) info
Market Cap: $25.807M info
EDSA
Oct 23, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.77
Real-time Price: $1.91 info
Change: -$0.860 (-31%) info
Market Cap: $25.807M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $1.91 info
Change: -$0.710 (-27%) info
Market Cap: $25.807M info